ADI-001 is an allogeneic gamma delta CAR T-cell therapy that targets the B-cell antigen CD20. The Food and Drug Administration (FDA) has granted Fast Track designation to ADI-001 for the treatment of ...
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for ...
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for ...
(RTTNews) - IN8bio, Inc. (INAB) announced the launch of its next-generation Gamma-Delta T-cell engager or TCE platform INB-600, designed to overcome the limitations of existing Gamma-Delta TCE ...
Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells with robust potency INB-619, a next generation γδ TCE targeting CD19, ...
IN8bio, Inc., a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies for cancer and autoimmune diseases, will participate in the Immuno-Oncology 360° Conference 2025 from ...
SINGAPORE, Nov. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its ...
A laboratory study out of Roswell Park Comprehensive Cancer Center outlines a new way to boost the effectiveness of chimeric antigen receptor (CAR) T-cell therapy in solid-tumor cancers, resulting in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results